ClinicalTrials.gg
CompletedNCT04914429Updated Oct 12, 2023

A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis

A Phase 4 interventional study of Guselkumab and Placebo in Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 26 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Enrollment
7th of 29
327 · median 120
Started
2021
with 1 other
Phase 4
10 of 29
6 open now
Registered
18th of 29
by date
Lead sponsor
9 of 29
Janssen Research & Development, LLC

Among the 29 studies testing guselkumab in Psoriasis, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 10 in phase 4, and was the 18th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in the treatment of Chinese participants with moderate to severe plaque psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of plaque psoriasis with or without psoriatic arthritis for at least 6 months before screening
  • A woman of must have a negative urine pregnancy test at screening and at baseline
  • Agree not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug
  • Agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet (UV) light sources during study
  • Must sign an form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Has a nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)
  • Has a history of or current signs or symptoms of liver or renal insufficiency (estimated below 60 milliliter/minute [mL/min]); significant, progressive, or uncontrolled cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Currently has a or has a history of within 5 year before screening (exceptions are nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study drug administration and cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before screening, or malignancy, which is considered cured with minimal risk of recurrence)
  • History of, or ongoing, chronic or recurrent infectious disease, including but not limited to, recurrent sinopulmonary infections, bronchiectasis, recurrent renal/urinary tract infection (example, recurrent pyelonephritis, recurrent cystitis), fungal infection (mucocutaneous candidiasis), an open, draining, or infected skin wound, or an ulcer
  • Has previously received guselkumab
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
327 participants (actual)

Study arms

  • Experimental
    Group 1: Guselkumab

    Participants will receive guselkumab 100 milligrams (mg) by subcutaneous (SC) injection at Weeks 0, 4, and then every 8 weeks (q8w) through Week 44. Participants will receive matching placebo at Week 16.

    Drug: Guselkumab · Drug: Placebo

  • Placebo comparator
    Group 2: Placebo

    Participants will receive placebo SC injection for guselkumab at Weeks 0, 4, and 12, and then cross over at Week 16 to receive guselkumab 100 mg SC injection at Weeks 16 and 20 and q8w thereafter through Week 44.

    Drug: Guselkumab · Drug: Placebo

Interventions

  • Guselkumab 100 mg will be administered as a SC injection.

    Also known as: TREMFYA

  • DrugPlacebo

    Matching placebo will be administered as a SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response is defined as greater than or equal to (\>=)90 percent (%) improvement in PASI score.

    Time frame: Week 16

  2. Percentage of Participants who Achieve an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

    The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 16

  3. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to Week 56

  4. Number of Participants with Serious Adverse Events (SAEs)

    SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.

    Time frame: Up to Week 56

  5. Number of Participants with Reasonably Related Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to Week 56

  6. Number of Participants with AEs Leading to Discontinuation of Study Intervention

    Number of participants with AEs leading to discontinuation of study intervention will be reported.

    Time frame: Up to Week 56

  7. Number of Participants with Infections

    Number of participants with infections including serious infections, and infections requiring oral or parenteral antimicrobial treatment will be reported.

    Time frame: Up to Week 56

  8. Number of Participants with Serious Hypersensitivity Reactions

    Number of participants with serious hypersensitivity reactions (such as anaphylaxis, urticaria, pruritis, angioedema, wheezing, dyspnea, or hypotension) will be reported.

    Time frame: Up to Week 56

  9. Number of Participants with Injection-site Reactions

    An injection-site reaction is any unfavorable or unintended sign that occurs at the study drug injection site. Injection sites will be evaluated for reactions and any injection-site reaction will be recorded as an AE.

    Time frame: Up to Week 56

  10. Number of Participants with Change from Baseline in Laboratory Abnormalities

    Number of participants with change from baseline in laboratory abnormalities (chemistry, hematology) will be reported.

    Time frame: Up to Week 56

  11. Number of Participants with Laboratory Abnormalities with Maximum Toxicity Grades

    Number of participants with laboratory abnormalities (hematology, chemistry) with maximum toxicity grades will be reported. A higher grade indicates more severity.

    Time frame: Up to Week 56

  12. Number of Participants with Change from Baseline in Vital Signs

    Number of participants with change from baseline in vital signs (temperature, heart rate, respiratory rate, blood pressure) will be reported.

    Time frame: Up to Week 56

Secondary outcomes

  1. Percentage of Participants who Achieve a PASI 100, PASI 75, and PASI 50 Response Over Time

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100, 75, and 50 response is defined as 100%, \>=75%, and \>=50% improvement in PASI score respectively.

    Time frame: Week 0, 4, 12, 16, 20, 28, 36, 44, 48

  2. Percentage of Participants who Achieve a PASI 90 Response Over Time

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response is defined as \>=90% improvement in PASI score.

    Time frame: Week 0, 4, 12, 16, 20, 28, 36, 44, 48

  3. Percentage of Participants who Achieve an IGA Score of Cleared (0) or Minimal (1) Over Time

    Percentage of participants who achieve an IGA score of cleared (0) or minimal (1) over time will be reported.

    Time frame: Week 0, 4, 12, 16, 20, 28, 36, 44, 48

  4. Change from Baseline in Dermatology Life Quality Index (DLQI) Score Over Time

    The DLQI is a dermatology-specific quality of life (QoL) instrument designed to assess the impact of the disease on a participant's QoL. It is a 10 item patient-reported outcome(s) (PRO) questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The DLQI produces a numeric score that can range from 0 to 30. A higher score indicates more severe disease.

    Time frame: Baseline, Week 4, 16, 28, 48

  5. Percentage of Participants who Maintain PASI 90 Response at Week 48 Among Participants who were PASI 90 Responders at Week 16 in Guselkumab Group

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response is defined as \>=90% improvement in PASI score.

    Time frame: Week 48

  6. Percentage of Participants who Maintain IGA Score of Cleared (0) or Minimal (1) at Week 48 Among Participants who Achieved IGA 0/1 at Week 16 in Guselkumab Group

    Percentage of participants who maintain IGA score of cleared (0) or minimal (1) at Week 48 among participants who achieved IGA 0/1 at Week 16 in guselkumab group will be reported.

    Time frame: Week 48

  7. Percentage of Participants who Achieve an IGA Score of Cleared (0) and an IGA Score of Mild or Better (Less Than or Equal to [<=] 2) Over Time

    Percentage of participants who achieve an IGA score of cleared (0) and an IGA score of mild or better (\<=2) over time will be reported.

    Time frame: Week 0, 4, 12, 16, 20, 28, 36, 44, 48

  8. Percentage of Participants who Achieve a DLQI Score of 0 or 1 Over Time Among Participants with Baseline DLQI Greater Than (>) 1

    Percentage of participants who achieve a DLQI score of 0 or 1 over time among participants with baseline DLQI \>1 will be reported.

    Time frame: Week 0, 4, 16, 28, 48

  9. Percentage of Participants With a Reduction of 5 or More Points in DLQI Score Over Time

    Percentage of participants with a reduction of 5 or more points in DLQI score over time will be reported.

    Time frame: Week 0, 4, 16, 28, 48

  10. Percent Change from Baseline in Nail Psoriasis Severity Index (NAPSI) Over Time Among Participants with Nail Psoriasis at Baseline

    The NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0-4 (A higher score indicates more severity). The sum of these scores is the total NAPSI score (0=no psoriasis to 8=psoriasis present in all 4 quadrants of the target nail).

    Time frame: Baseline, Week 16, 28, 36, 48

  11. Percentage of Participants with an Scalp-Specific Investigator Global Assessment (ss-IGA) Score of Absence of Disease (0) or Very Mild Disease (1) Over Time Among Participants with Scalp Psoriasis and an ss-IGA Score >=2 at Baseline

    The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: absence of disease (0), very mild disease (1), mild disease (2), moderate disease (3), and severe disease (4).

    Time frame: Week 0, 16, 28, 36, 48

  12. Serum Concentration of Guselkumab Over Time

    Serum concentrations of guselkumab over time will be reported.

    Time frame: Week 0, 4, 16, 20, 36, 44, 56

  13. Number of Participants with Antibodies to Guselkumab

    Number of participants with antibodies to guselkumab through week 56 will be reported.

    Time frame: Week 0, 16, 44, 56

  14. Maximum Titer of Antibodies to Guselkumab Through Week 56

    Maximum titer of antibodies to guselkumab through Week 56 will be reported.

    Time frame: Week 0, 16, 44, 56

07

Study locations

26 sites
  • Peking University Third Hospital
    Beijing, 100191, China
  • Beijing Tongren Hospital, CMU
    Beijing, 100730, China
  • Xiangya Hospital Central South University
    Changsha, 410008, China
  • The second Xiangya Hospital of Central South University
    Changsha, 410011, China
  • West China Hospital,Sichuan University
    Chengdu, 610041, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, 400016, China
  • The First Hospital Affiliated to AMU (Southwest Hospital)
    Chongqing, 400038, China
  • Fujian Medical University
    Fuzhou, 350005, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, 510091, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, 310004, China
  • The Second Affiliated Hospital of Zhejiang University College of Medicine
    Hangzhou, 310009, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, 310016, China
  • The 1st affiliated hospital of Anhui Medical University
    Hefei, 230022, China
  • Skin Disease Hospital of Shandong Province
    Jinan, 250022, China
  • Jiangsu Province Hospital
    Nanjing, 210029, China
  • Hospital of Dermatology, Chinese Academy of Medical Science
    Nanjing, 210042, China
  • Shanghai Ruijin Hospital
    Shanghai, 200025, China
  • Huashan Hospital Fudan University
    Shanghai, 200040, China
  • Shanghai skin disease hospital
    Shanghai, 200050, China
  • University of Hong Kong-Shenzhen Hospital
    Shenzhen, 518053, China
  • Tianjin Medical University General Hospital
    Tianjin, 300052, China
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, 300120, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, 325000, China
  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, 430022, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, 710004, China
  • Henan province people's hospital
    Zhengzhou, 450003, China
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Sep 2023, 25 months.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 25 months is above that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2021
First posted
Jun 4, 2021
StartActual
Aug 25, 2021
Primary completionActual
Sep 26, 2023
CompletionActual
Sep 26, 2023
Last update
Oct 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04914429
Responsible party
Sponsor
First posted
Jun 4, 2021
Start date
Aug 25, 2021
Primary completion
Sep 26, 2023
Completion
Sep 26, 2023
Last update
Oct 12, 2023

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion